Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma
Cancers · 13.05.2026 · 18 (10) · 1586
DOI: 10.3390/cancers18101586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 13.05.2026. Verfasst von Nils Ludwig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 5-Haematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 910…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Rationale
Oral squamous cell carcinoma (OSCC) carries a poor prognosis despite advances in multimodal therapy. Nanomedicine represents a compelling strategy to enhance targeted drug delivery and improve therapeutic outcomes. Here, we investigated sEV-mediated delivery of curcumin as a novel therapeutic approach for OSCC.
Methods
Small extracellular vesicles (sEVs) were isolated from Jurkat cells by size-exclusion chromatography and loaded with curcumin via sonication to generate JCsEV. Functional effects were assessed in vitro using wound healing, transwell invasion, and metabolic activity assays across multiple cancer cell lines. Therapeutic efficacy in vivo was evaluated in the 4-nitroquinoline 1-oxide (4-NQO) immunocompetent murine model of oral carcinogenesis. Female C57BL/6J mice received intraperitoneal treatment for four weeks with PBS, free curcumin, unloaded JsEV, or JCsEV. Tumor number, tumor burden, and body weight changes were assessed at the experimental endpoint.
Results
In vitro, JCsEV significantly inhibited tumor cell migration, invasion, and metabolic activity compared with controls (p < 0.05). In vivo, treatment with JCsEV significantly reduced tumor number and tumor burden in the 4-NQO model (p < 0.01). In addition, body weight loss was reduced in JCsEV-treated mice compared with controls. Conclusion: sEV-mediated delivery of curcumin effectively suppresses tumor progression in experimental OSCC. These findings establish proof-of-concept for sEV-based nanomedicine as a therapeutic strategy for OSCC and provide a compelling rationale for further translational investigation of sEVs as drug delivery platforms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine 5-Haematology and Oncology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
- UPMC Hillman Cancer Center, Pittsburgh, PA 15213, USA.
- Department of Medical Oncology, Heidelberg University Hospital, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
ORCID-Profile: Nils Ludwig
Förderung
- National Institutes of Health
Zitieren
APA
Ludwig, N., Feldmann, C., Spoerl, S., & Yerneni, S. S. (2026). Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma. Cancers, 18(10), 1586. https://doi.org/10.3390/cancers18101586
Vancouver
Ludwig N, Feldmann C, Spoerl S, Yerneni SS. Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma. Cancers. 2026;18(10):1586. doi:10.3390/cancers18101586
BibTeX
@article{Ludwig2026,
author = {Ludwig, Nils and Feldmann, Carolin and Spoerl, Silvia and Yerneni, Saigopalakrishna S},
title = {Extracellular Vesicle-Mediated Delivery of Curcumin Suppresses Tumor Progression in Murine Oral Squamous Cell Carcinoma},
journal = {Cancers},
year = {2026},
volume = {18},
number = {10},
pages = {1586},
doi = {10.3390/cancers18101586}
}
EUVIMED